Ajaz Sheikh, MD
Neurology · Toledo, OHNPI 1932401221
Payments from drug & device makers
Across 180 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$514
- Jazz Pharmaceuticals Inc.$392
- UCB, Inc.$381
- Neuropace, Inc.$316
- SK Life Science, Inc.$242
- Neurelis, Inc.$233
- plus $1K from 34 others
What the payments were for
- Food & beverage$3,23591%
- Education$3369%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $514 |
| Jazz Pharmaceuticals Inc. | 13 | $392 |
| UCB, Inc. | 19 | $381 |
| Neuropace, Inc. | 3 | $316 |
| SK Life Science, Inc. | 14 | $242 |
| Neurelis, Inc. | 13 | $233 |
| Teva Pharmaceuticals USA, Inc. | 7 | $152 |
| Eisai Inc. | 5 | $132 |
| Bristol Myers Squibb | 7 | $121 |
| Biocodex, Inc. | 2 | $112 |
| Harmony Biosciences LLC | 2 | $97 |
| Novartis | 5 | $75 |
| AstraZeneca | 4 | $66 |
| Acadia Pharmaceuticals Inc | 4 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Piramal Critical Care | 3 | $53 |
| Kyowa Kirin, Inc. | 3 | $51 |
| Inspire Medical Systems, Inc. | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| CSL Behring | 2 | $33 |
| Pfizer | 2 | $33 |
| Aquestive Therapeutics, Inc. | 2 | $32 |
| Lilly USA, LLC | 2 | $27 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Merck | 2 | $27 |
| Amgen | 2 | $26 |
| Argenx US, Inc. | 1 | $22 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Pulmonx Corporation | 1 | $18 |
| Sanofi | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| EMD Serono, Inc. | 1 | $13 |
| Zogenix Inc. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS Neurostimulator Kit$295
- Briviact$125
How this compares
$3,571 in reported general payments places this provider in the 55th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 27 | $224,842 |
| Nurtec OdtRimegepant Sulfate | 52 | $68,528 |
| Rufinamide | 24 | $37,019 |
| KeppraLevetiracetam | 25 | $32,242 |
| ZonegranZonisamide | 13 | $30,527 |
| Aimovig AutoinjectorErenumab-Aooe | 39 | $30,382 |
| BriviactBrivaracetam | 15 | $27,244 |
| VimpatLacosamide | 22 | $26,128 |
| FycompaPerampanel | 23 | $25,654 |
| XcopriCenobamate | 16 | $16,173 |
| Emgality PenGalcanezumab-Gnlm | 21 | $15,118 |
| NayzilamMidazolam | 11 | $13,048 |
| Levetiracetam | 197 | $11,606 |
| Lacosamide | 68 | $10,290 |
| Divalproex Sodium ErDivalproex Sodium | 53 | $7,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $33 | $68,52852 claims |
| UCB, Inc.Briviact, Vimpat, Nayzilam | $381 | $66,42048 claims |
| Eisai Inc.Fycompa, Dayvigo | $132 | $29,28334 claims |
| SK Life Science, Inc.Xcopri | $242 | $16,17316 claims |
| MerckBelsomra | $27 | $5,64313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 702 neurology providers in Ohio.
Other neurology in Toledo
- Lawrence ElmerToledo$1.5M
- Mouhammad JumaaToledo$1.1M
- Howard SchechtToledo$564K
- Joel VandersluisDayton$12.3M
- Jerry MendellColumbus$11.5M
- Lawrence GoldstickDayton$6.9M
- Douglas ScharreColumbus$6.8M
- Robert BermelCleveland$6.4M
- Aaron BosterColumbus$6.3M
- Ryan DrakeCanton$5.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.